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Background
Low densities of tumor infiltrating lymphocytes (TILs)
predict colorectal cancer (CRC) post-surgical recurrence,
the likelihood of progression also depending upon
tumor stage and microsatellite (MS) status. We bench-
marked FoxP3+TIL and CD3+TIL densities as predictor
of postsurgical recurrence.
Methods
FoxP3+ and CD3+TIL densities were measured as the
percentage of immune-reactive area (IRA%) at the
tumor invasion front, in a consecutive series of 413
patients (pts) undergone radical surgery for pT3-pT4,
stage II (n=211) and III (n=202) CRC, characterized for
MS status. Recursive partitioning, as well logistic uni-
variate, interaction, and multivariate analysis were
employed for the integrated examination of pathological
and immune markers in predicting recurrence.
Results
In a recursive classification tree, nodal status was the
main prognostic factor, discriminating higher recurrence
rate for stage III (70/202; 34.7%;) than for stage II (32/
211, 15.2% P<.001) pts. Within stage II, 0.23%FoxP3
+IRA cut-off divided recurrences in 8/127 (6.3%) pts
with high (>0.23%) FoxP3+TILs, and in 24/84 (28.6%;
P<.001) pts with low (≤0.23%) FoxP3+TILs. Within the
latter group, CD3+IRA% further branched recurrences,
that occurred in 7/39 (15.2%) pts with IRA>1.86%, but
in 17/38 (44.7%; P=.003) pts with less IRA%. Differently,
TIL densities did not predict recurrence in stage III.
Interaction analysis revealed that the prognostic effects
of FoxP3+and CD3+TIL densities were significantly
(P<0.05) modified by nodal and MS-status status. ROC
curve analysis in stage II pts with MSS CRC confirmed
the cut-offs identified by recursive partitioning. At mul-
tivariate, low (<0.23%IRA) FoxP3+ and (<1.86% IRA)
CD3+TILs were both independent recurrence predictors
(O.R, 10.22 and 7.85, respectively; both P<.001), and
concomitant low-FoxP3+ and -CD3+TILs conferred the
highest recurrence risk (O.R. 12.64; P<.001). Among
stage II pts, the low-FoxP3+ and -CD3+TIL signature
identified 61% (17/28) of all MSS CRC recurrences,
representing 71% (17/24) of post-surgical metastasis (O.
R. 18.43; 95%C.I. 6.68-50.86), while none of 58 pts with
high-FoxP3+ and -CD3+TIL experienced recurrences.
Conclusions
FoxP3+ and CD3+TIL amount, plus tumor MS status
efficiently stratify the risk of relapse of stage II CRCs,
and may help in tailoring the post-surgical management
of patients.
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